Urticaria (hives) - Clinical trials 

  • Clinical trials

Clinical trials for Urticaria (hives)

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Urticaria (hives). For all clinical trials, go to clinical trials search

This list shows clinical trials for Urticaria (hives)

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Urticaria (hives)
Title Recruitment status Location
Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of Icatibant vs. oral Tranexamic acid for the treatment of hereditary angioedema (HAE). - FAST 2 Not Recruiting United Kingdom
Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks - C1-INH HAE study Not Recruiting United Kingdom
A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morning vs. Desloratadine 5 mg oral capsules once daily in the morning in patients suffering from Chronic Idiopathic Urticaria (CIU) Not Recruiting United Kingdom
Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of Icatibant vs. oral Tranexamic acid for the treatment of hereditary angioedema (HAE). - FAST 2 Not Recruiting United Kingdom
Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema - EASSI - Evaluation of the Safety of Self-administration with Icatibant Not Recruiting United Kingdom
Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema - EASSI - Evaluation of the Safety of Self-administration with Icatibant Not Recruiting United Kingdom
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Not recruiting United Kingdom
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Not recruiting United Kingdom
EASSI - Evaluation of the Safety of Self-Administration With Icatibant Not recruiting United Kingdom
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema Not Recruiting United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member